Saluda Medical Evoke SCS System
Saluda Medical Pty, Ltd. · Decision date Feb 28, 2022
What did the FDA approve?
FDA records P190002 as an original PMA application. The recorded decision is approval, dated Feb 28, 2022.
FDA approval order statement
Approval for the Evoke SCS System. This device is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbsincluding unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Neurology
- Decision date
- Feb 28, 2022
Regulatory record facts
- Identifier
- P190002
- Regulatory pathway
- Premarket approval application
- Applicant
- Saluda Medical Pty, Ltd.
- Product code
- LGW
- Decision code
- APPR
- Decision date
- Feb 28, 2022
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.
- Applicant
- Saluda Medical Pty, Ltd.
- Product code
- LGW
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P190002 received
Application receipt date recorded by FDA.
P190002 · FDA decision
APPR
P190002/S051 · Related supplement
Saluda Medical Evoke SCS System
P190002/S052 · Related supplement
Saluda Medical Evoke SCS System
Timeline entries are records held by MedtechLedger for P190002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P190002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Saluda Medical Evoke SCS SystemP190002/S051 | Saluda Medical Pty, Ltd. | PMA supplement | Oct 15, 2026 | FDA |
Saluda Medical Evoke SCS SystemP190002/S052 | Saluda Medical Pty, Ltd. | PMA supplement | Oct 16, 2026 | FDA |
Explore the linked device profile
Other records with product code LGW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Saluda Medical Pty, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Level 1, 407 Pacific Hwy., Atarmon, NSW 2064
Sources and methodology
- Original FDA record: P190002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



